Beactica Therapeutics is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Beactica Therapeutics. Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platform. Founded in 2006 based on research carried out at Uppsala University Beactica has established a reputation as the leader in SPR biosensor-based small molecule drug discovery. Beactica is the discovery partner chosen by companies like J&J, Boehringer Ingelheim, Almac and Medivir to advance prioritized drug discover programmes. These companies have benefited from Beactica's unique expertise and proprietary technologies to progress projects with needs related to fragment-based lead generation, identification of allosteric inhibitors, optimization of interactions kinetics and complex mechanism of actions.
Company size
11-50 employees